tradmap

MED Financials MEDIFAST INC

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 29.1% per year over the past 5 years.
  • Free cash flow has declined 61.0% per year over the past 5 years.

Shareholder returns

  • Dividends have been paid for 10 consecutive years, consuming 15.6% of free cash flow.
  • The dividend has declined 67.4% per year over the past 5 years.
Revenue & net income
-$19M $790M $2B $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-5% 34% 74% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-10% 42% 93% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
$0 $89M $178M 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $82M $164M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$200M -$3M $195M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $386M -$19M 71.3% -3.7% -9.6% -7.7% $1M $89M
2024 $602M $2M 73.8% 0.5% 1.0% 0.7% $17M $91M
2023 $1.1B $99M 72.4% 11.8% 49.1% 31.9% $141M $94M
2022 $1.6B $144M 71.3% 11.6% 92.9% 45.5% $178M $88M
2021 $1.5B $164M 73.9% 14.2% 81.0% 41.2% $60M $104M
2020 $103M 65.4% 37.3% $139M $164M
2019 $78M 74.3% 40.0% $74M $77M
2018 $56M 51.1% 32.9% $56M $81M
2017 $28M 26.0% 19.0% $40M $75M
2016 $18M 18.6% 14.7% $22M $52M
2015 $20M 22.6% 17.3% $27M $42M
2014 $13M 16.4% 11.4% $19M $24M
2013 $24M 24.4% 18.1% $31M $0 $36M
2012 $16M 17.5% 12.2% $32M $3M $40M
2011 $19M 25.3% 17.5% $21M $4M $14M

Valuation over time

How the market has priced MED against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 49.3 98.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 0.4 0.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 17.8 35.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is MED growing its revenue and profit?

Over the past 5 years, MEDIFAST INC's revenue has declined 29.1% per year. These are computed facts, not advice.

How much debt does MED have?

As of FY2025, MEDIFAST INC reported — of total debt against $89M of cash.

What is MED's profit margin?

In FY2025, gross margin was 71.3%, operating margin -3.7%, and net margin -4.9%.

What is MED's P/E ratio?

As of Sep '26, MEDIFAST INC traded at a price-to-earnings ratio of about 61.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.